Farmas USA

TEVA
https://seekingalpha.com/news/3575178-teva-pulls-out-of-price-fixing-talks-doj-in-gambit-to-avoid-charges?utm_medium=email&utm_source=seeking_alpha&mail_subject=teva-teva-pulls-out-of-price-fixing-talks-with-the-doj-in-gambit-to-avoid-charges&utm_campaign=rta-stock-news&utm_content=link-1

Mil gracias por la respuesta tan completa investing_saints

me habeis puesto los dientes largos....venga os acompaño también...con los 29 me conformo :-)

KPTI

KPTI

Pues la están moviendo a su antojo. He visto en directo como movían el precio para pintar el gráfico diario en máximo creciente y mínimo decreciente (confiemos a esta hora ya) y justo después vuelta directa a 19,14 y 19,10. Confiaremos también en que mañana sigan pintando máximos crecientes.

No estaría mal que alguien mirara cómo van de cash y colocaciones...

Mañana vamos,,, a descansar un poquito,,   no!!  :))))

Hicieron un offering en Marzo creo.. Si habra que mirar el resto el finde

Y los 25 los ha rechazado en Los dos ultimos intentos en los ultimos años.... Bengal, pongo el limite en 25 en vez de 29😉

KPTI

AMRN
Potencial banderín en formación

Datos financieros 1st Quarter. Por lo que entiendo tienen 385.2 millones en caja y queman unos 52 al trimestre. El offering que hicieron en Marzo fueron como unos 150 millones a 24 dólares. A ver si con el hype de ASCO y la aplicación del NDA filling a finales de este mes podemos volver a los 25.  Framus, échale unas rayuelas si estás con ganas please. 

irst Quarter 2020 Financial Results

Net product revenue: Net product revenue for the first quarter of 2020 was $16.1 million. Karyopharm commenced sales of XPOVIO in the U.S. during the third quarter of 2019 and therefore did not have net product revenue during the first quarter of 2019.

License and other revenue: License and other revenue for the first quarter of 2020 was $2.1 million, compared to $0.2 million for the first quarter of 2019. The increase was  driven in part by the recognition of $1.1 million pursuant to our license agreement with Antengene.

Cost of sales: Cost of sales were $0.8 million for the first quarter of 2020. Cost of sales reflects the costs of XPOVIO units sold and third-party royalties on net product revenue.

Research and development expenses (R&D): R&D expenses for the first quarter of 2020 were $34.0 million, compared to $38.0 million for the first quarter of 2019.

Selling, general and administrative expenses (SG&A): For the first quarter of 2020, SG&A expenses were $30.7 million, compared to $27.1 million for the first quarter of 2019. The increase in SG&A expenses compared to the prior year was due primarily to activities to support the U.S. commercialization of XPOVIO and in preparation for the potential launch of additional indications in 2020.

Interest expense: Interest expense for the first quarter of 2020 was $6.5 million, compared to $3.0 million for the first quarter 2019. The increase in interest expense is attributable to the imputed interest on the deferred royalty obligation Karyopharm has with HealthCare Royalty Partners.

Net loss: Karyopharm reported a net loss of $52.9 million, or $0.78 per share, for the first quarter of 2020, compared to a net loss of $66.2 million, or $1.09 per share, for the first quarter of 2019. Net loss includes non-cash stock-based compensation expense of $5.2 million and $3.9 million for the 2020 and 2019 quarters, respectively.

Cash position: Cash, cash equivalents, restricted cash and investments as of March 31, 2020 totaled $385.2 million, compared to $265.8 million as of December 31, 2019. 

KPTI